Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-Hodgkin's lymphoma (NHL) of one of the following types:~  * Diffuse large B-cell~ * Composite (at least 50% of tumor showing diffuse histology)~ * Diffuse mixed cell~ * Immunoblastic~* Relapsed or refractory disease sensitive to initial or subsequent conventional therapy (at least a partial response)~* Eligible for high-dose carmustine, etoposide, cytarabine, and melphalan protocol and autologous bone marrow transplantation or peripheral blood stem cell transplantation~* Evidence of CD20 antigen expression in tumor tissue~* Bidimensionally measurable disease~* Adequate peripheral blood stem cells~  * At least 15,000,000 CD34+ cells/kg or~ * At least 25,000 granulocyte macrophage colony-forming units/kg~* Age: 19 to 70~* Performance status: Karnofsky 70-100%~* Life expectancy: at least 4 months post-transplantation~* Bilirubin less than 2.0 mg/dL~* Creatinine less than 2.0 mg/dL~* Cardiac ejection fraction at least 40% for any of the following criteria:~  * Age 60 and over~ * Significant cardiac history (myocardial infarction or congestive heart failure)~ * Received greater than 350 mg/m\^2 of prior doxorubicin~* DLCO at least 50% of predicted~* HIV negative~* Fertile patients must use effective contraception during and for at least 6 months after study participation~* At least 4 weeks since prior biologic therapy and recovered~* Human antimouse antibody negative~* At least 4 weeks since prior cytotoxic chemotherapy and recovered~* At least 4 weeks since prior radiotherapy and recovered~* At least 4 weeks since prior immunosuppressants and recovered~Exclusion Criteria:~* No progressive disease in a field that has been previously irradiated with more than 3,500 cGy within the past year~* No known brain or leptomeningeal metastases~* No active obstructive hydronephrosis~* No New York Heart Association class III or IV heart disease~* No evidence of severe organ dysfunction~* No other major medical illnesses~* No active infection requiring IV antibiotics~* No other malignancy within the past 5 years except adequately treated skin cancer or carcinoma in situ of the cervix~* Not pregnant/negative pregnancy test~* No prior peripheral blood stem cell transplantation following high-dose chemotherapy or chemoradiotherapy~* No other concurrent biologic therapy for NHL~* No concurrent steroids except maintenance-dose steroids for noncancerous disease~* No concurrent external beam radiotherapy for NHL~* No other concurrent participation on protocol involving non-FDA-approved drugs or biologics

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Iodine-131 Anti-B1 Antibody/BEAM/autologous hematopoietic stem cell transplantation (AHSCT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete